How MK-677 (Ibutamoren) Affects IGF-1

MK-677 raises IGF-1 through continuous stimulation of endogenous GH release:

1. Ghrelin receptor activation: MK-677 binds the growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus, triggering sustained GH secretion over its 24-hour half-life. This is distinct from pulsatile GHRP/GHRH analogs that produce discrete GH pulses with inter-pulse recovery.
2. Hepatic IGF-1 synthesis: Sustained GH exposure upregulates hepatic IGF-1 production continuously. The liver is the primary source of circulating IGF-1, and GH is the dominant regulator of its synthesis.
3. Non-pulsatile pattern: Physiological GH release is pulsatile (6-12 pulses per day, primarily during sleep). MK-677 overrides this pattern with continuous stimulation, resulting in higher trough GH levels and correspondingly higher sustained IGF-1 compared to pulsatile secretagogues at equivalent total GH output.
4. Dose-dependent ceiling: The IGF-1 response to MK-677 follows a dose-response curve with diminishing returns at higher doses. The Nass et al. (2008) trial documented IGF-1 restoration to young-adult levels (approximately 1.5-fold increase from baseline) at 25 mg/day in elderly subjects over 12 months.

Low dose (10-15 mg/day):

• IGF-1 typically increases 20-40% above baseline
• Most users reach the upper-normal range for their age
• Effect stabilises within 2-4 weeks

Standard dose (25 mg/day):

• IGF-1 increases approximately 50-100% above baseline
• Chapman et al. (1996) documented mean IGF-1 rising from 141 to 265 mcg/L at 4 weeks (88% increase)
• Elderly subjects reached IGF-1 levels normal for young adults
• Effect is sustained with continuous daily dosing

Comparative context:

• MK-677 at 25 mg/day produces IGF-1 elevation roughly equivalent to 2-3 IU/day of exogenous GH
• Higher IGF-1 elevations require exogenous GH at higher doses; MK-677 has a ceiling effect determined by pituitary capacity

Timeline: IGF-1 begins rising within 1-2 weeks, reaches near-maximum effect by 4-6 weeks, and remains elevated for the duration of use. After cessation, IGF-1 returns to baseline within 2-4 weeks as GH stimulation ceases.

Baseline: Obtain IGF-1 before starting MK-677. Age-matched reference ranges are important because "normal" IGF-1 declines with age.

During use:

• IGF-1: at 4 weeks (to confirm response), then every 3 months
• Target: upper-normal range for your age group. Avoid sustained supraphysiological levels.
• If IGF-1 exceeds 1.5x the upper limit of the age-matched reference range, consider dose reduction

Important considerations:

• IGF-1 lab values vary by assay. Use the same laboratory for serial measurements.
• Fasting state does not significantly affect IGF-1 levels (unlike glucose or insulin)
• Time of day does not substantially affect IGF-1 due to its long half-life (15-20 hours)

Optimising the IGF-1 response:

• Take MK-677 consistently at the same time daily (most users prefer bedtime to sleep through the appetite increase)
• Adequate protein intake (1.6-2.2 g/kg) supports hepatic IGF-1 synthesis
• Caloric deficit blunts IGF-1 response; avoid severe restriction during MK-677 use

If IGF-1 is too high (supraphysiological):

• Reduce dose from 25 mg to 12.5-15 mg
• Implement 5-on/2-off dosing to lower average GH stimulation
• Monitor for downstream effects: glucose, insulin, joint pain, water retention

If IGF-1 response is poor (less than 20% increase):

• Verify product authenticity (SARM/peptide product mislabelling is common)
• Ensure adequate sleep (GH response is blunted with sleep deprivation)
• Check thyroid function (hypothyroidism blunts GH and IGF-1 responses)
• Consider that individual pituitary responsiveness varies significantly